Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Chewy

During the pandemic lockdowns, adopting pets became popular, resulting in a whopping 5 million more pets being added to households in the U.S. Morgan Stanley predicts that the overall spending in the pet industry will grow at a compounded annual growth rate of 8% and will be worth $277 billion by 2030, reaching $1,320 per pet per household in 2025 and $1,897 by 2030. Thus, let's take a look at two industry-leading stocks poised to benefit from this trend.

2 Pet Stocks Poised to Benefit From Industry Growth

Peter Drucker, who is widely considered the father of modern management, famously said that a business only has two basic functions and Zoetis is thriving on both these fronts. Numbers continue to trend in the right direction despite looming threats on the horizon.

Zoetis: Great Business, Fair Price

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DrivenToCare--Today, the Zoetis Foundation announced that it will distribute $5.3 million during its first round of 2023 grants, supporting 21 initiatives impacting 15 countries to help enable thriving professions and livelihoods for livestock farmers and veterinary professionals, as well as relief efforts for those impacted by the earthquake in Türkiye.

Zoetis Foundation Announces First Round of 2023 Grants to Advance Farmer and Veterinarian Education, Livelihoods and Well-being

Cigna

Domino's Pizza

Lowe's

Mastercard

MarketAxess Holdings

Monolithic Power Systems

Rollins

Charles Schwab

Sherwin-Williams

SS&C Technologies Hlds

Tractor Supply

Visa

W. R. Berkley

I present my top 15 high-growth dividend stocks to consider during the month of April. The watchlist posted a gain of 2.02% in March, finishing ahead of VIG but trailing SPY.

My Top 15 High-Growth Dividend Stocks For April 2023

Abbott Labs

CVS Health

In 2022, healthcare stocks surpassed the S&P 500. But in 2023, they are not doing so well.

3 Healthcare Stocks to Watch As the Industry Evolves

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #LifeatZoetis--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 4, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.

Zoetis to Host Webcast and Conference Call on First Quarter 2023 Financial Results

Zoetis is in the enviable position of being the world's only pure-play global animal-health company at a time when spending on pets and livestock is rising. A pullback in its shares makes this a good time to buy.

Zoetis Stock Will Stir Your Animal Spirits

Alaska Air Group

Bio-Rad Laboratories

Delta Air Lines

GE HealthCare Technologies Inc

Halliburton

Jacobs Solutions Inc

Synopsys

Targa Resources

Vici Properties

Finding S&P 500 stocks that analysts agree on is rare. So when you see nearly unanimous agreement on some, that's quite a statement.

Analysts Agree Now's The Time To Buy These 10 Promising Stocks

Danaher

Old Dominion Freight Line

Markets are in turmoil. Hence, in this article, we start with a discussion of the risks facing investors and why I believe in attractive buying opportunities this year. While I understand that investors often opt for higher-yielding investments, I will explain why investments in low-yielding dividend-growth stocks come with benefits.

3 Awesome Dividend Growth Stocks To Buy During A Bear Market

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) has been recognized by Ethisphere, a global leader in defining and advancing the standards of ethical business practices, as one of the 2023 World's Most Ethical Companies. In 2023, 135 honorees were recognized, spanning 19 countries and 46 industries. Zoetis is one of three pharmaceutical companies and the only standalone animal health company included on the list.

Zoetis Named One of the World's Most Ethical Companies by Ethisphere

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) will participate in the TD Cowen Health Care Conference on Monday, March 6, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 11:10 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations.

Zoetis to Participate in the TD Cowen Health Care Conference

Best Buy

EOG Resources

MSCI

I present my top 15 high-growth dividend stocks to consider during the month of March. The watchlist posted loss of 2.94% in February, finishing behind VIG and SPY on the month.

My Top 15 High-Growth Dividend Stocks For March 2023

Collegium Pharmaceutical

COLL vs. ZTS: Which Stock Is the Better Value Option?

COLL vs. ZTS: Which Stock Should Value Investors Buy Now?

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DrivenToCare--Zoetis is pleased to receive a $15.3 million grant from the Bill & Melinda Gates Foundation to further develop and integrate innovative solutions to advance veterinary care and diagnostic services that will ultimately improve livestock health and productivity in Sub-Saharan Africa. The grant will help Zoetis to expand its original African Livestock Productivity and Health Advancement (A.L.P.H.A.

Zoetis Secures $15.3 Million Grant to Advance Sustainable Livestock Production and Improve Livelihoods in Sub-Saharan Africa

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2023 Animal Health Summit on Thursday, March 2, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:30 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.

Zoetis to Participate in the Bank of America Securities 2023 Animal Health Summit

Robust net-income growth and better-than-expected guidance brought the bulls back to the animal health specialist.

Why Zoetis Stock Shot Almost 9% Higher This Week

The stock is up 7.99 in the past week, after topping fourth-quarter views in its February 14 report. It also guided toward robust sales this year.

Zoetis, Pet-Med Specialist, Double-Digit Earnings Growth Ahead

Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.

Zoetis' (ZTS) Q4 Earnings in Line With Estimates, Revenues Beat

Zoetis Inc. (NYSE:ZTS ) Q4 2022 Earnings Conference Call February 14, 2023 8:30 AM ET Company Participants Steve Frank - Vice President, Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Jon Block - Stifel Erin Wright - Morgan Stanley Louise Chen - Cantor Nathan Rich - Goldman Sachs David Westenberg - Piper Sandler Chris Schott - JPMorgan Brandon Vazquez - William Blair Elliot Wilbur - Raymond James Operator Welcome to the Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.

Zoetis Inc. (ZTS) Q4 2022 Earnings Call Transcript

The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zoetis (ZTS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zoetis Inc. stock ZTS, +5.31% soared 5% Tuesday, after the animal health company topped revenue estimates for the fourth quarter and offered upbeat guidance for 2023. Parsippany, N.J.

Zoetis stock jump 5% after earnings beat and upbeat guidance

The animal health provider posts fourth-quarter revenue slightly above expectations and offers upbeat full-year guidance.

Zoetis Expects Sales Growth in 2023. The Stock Is Rising.

Zoetis (ZTS) delivered earnings and revenue surprises of 0% and 1.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Matches Q4 Earnings Estimates

Animal health giant Zoetis beat fourth-quarter sales expectations Tuesday and issued a strong 2023 outlook, leading ZTS stock to pop. The post Zoetis Snags A Quarterly Sales Beat And Issues A Strong 2023 Outlook appeared first on Investor's Business Daily.

Zoetis Snags A Quarterly Sales Beat And Issues A Strong 2023 Outlook

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2022 and provided full year guidance for 2023. The company reported revenue of $2.0 billion for the fourth quarter of 2022, which was an increase of 4% compared with the fourth quarter of 2021. On an operational1 basis, revenue for the fourth quarter of 2022 increased 9% compared with the fourth quarter of 2021, excluding the impact of foreign currency.

News for Zoetis Stock (ZTS)